Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq:
CHRS), today announced the appointment to its Board of Directors of
biopharma commercialization and market access expert Michael Ryan,
Pharm. D. Dr. Ryan has four decades of experience working in
academia and the biopharmaceutical industry bringing high-value
therapeutics to patients. Dr. Ryan’s distinguished career includes
most recently serving as Senior Vice President and Head for U.S.
and Worldwide Value, Access, Pricing and Health Economics and
Outcomes Research for Bristol Myers Squibb (“BMS”) for over seven
years. In this role, Dr. Ryan was responsible for more than 1,600
staff in 64 countries who were responsible for Strategic Payer
Marketing, Pricing and Contracting, Real World Evidence Generation
& Analytics, Access Clinical Development, Payer and Organized
Customer Sales, Market Access Scientific Liaison Program, and
Health Economics and Outcomes Research across the $44 billion BMS
worldwide biopharmaceutical and biomarker portfolio.
Dr. Ryan is Chair of the Board of the National Pharmaceutical
Council (“NPC”) and remains an Executive Advisor to BMS. He has
served on the boards of PhRMA, BIO, NPC, the University of Southern
California Schaeffer Center for Health Policy, and the Universities
of Michigan College of Pharmacy and the University of California at
San Francisco (“UCSF”) School of Pharmacy.
“We are thrilled to have a biopharma commercialization leader of
Dr. Ryan’s caliber join our Board of Directors. Mike brings to
Coherus his wealth of experience in market access and health
economics from his distinguished tenure at Bristol-Myers Squibb as
well as other companies at a national and global level,” said Denny
Lanfear, chief executive officer of Coherus. “His extensive
expertise will provide invaluable insights as we continue to launch
new products and advance our pipeline of innovative therapies to
extend patient survival.”
“I have spent my career focused on delivering patient benefit
and value across the biopharma industry and found Coherus’ mission
to develop new treatments to extend survival for cancer patients,
as well as increasing access to important medicines, highly
consistent with my own personal values,” said Dr. Ryan. “Coherus
has assembled a strong executive team to execute on a very sound
strategy, and I look forward to collaborating with them and the
Board to realize its full potential.”
Prior to joining BMS, Dr. Ryan spent 16 years at Amgen, serving
in roles including Vice President and General Manager of the
Nephrology Business Unit, where he was responsible for the P&L
and life cycle management of three products used to treat patients
with kidney disease: Epogen®, Aranesp® and Sensipar®.
Dr. Ryan is currently the founder and chief executive officer of
Koios Enterprises & Consulting, an executive consulting firm
specializing in patient access with a focus on evidence generation,
value, pricing and policy solutions that enable patient access. Dr.
Ryan is a graduate of the University of California at Los Angeles
and UCSF and completed his residency program at the University of
Michigan. After completing his residency, Dr. Ryan directed
clinical pharmacy research, education and operations at the
University of Pittsburgh School of Pharmacy and University of
Michigan College of Pharmacy.
About Coherus BioSciences
Coherus is a commercial-stage biopharmaceutical company focused
on the research, development and commercialization of innovative
immunotherapies to treat cancer. Coherus’ strategy is to build a
leading immuno-oncology franchise funded with cash generated
through net sales of its diversified portfolio of FDA-approved
therapeutics.
In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody,
in the United States and Canada. The Biologics License Application
for toripalimab in combination with chemotherapy as treatment for
recurrent or metastatic nasopharyngeal carcinoma is currently under
review by the FDA.
Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of
Neulasta®, CIMERLI® (ranibizumab-eqrn), a biosimilar of Lucentis®,
and YUSIMRY™ (adalimumab-aqvh), a biosimilar of Humira®.
Forward-Looking Statements
Except for the historical information contained herein, the
matters set forth in this press release are forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995, including,
but not limited to, statements regarding Coherus’ ability to build
its immuno-oncology franchise to achieve a leading market position;
Coherus’ ability to generate cash; Coherus’ investment plans;
Coherus’ ability to launch new products, advance its pipeline and
extend patient survival.
Such forward-looking statements involve substantial risks and
uncertainties that could cause Coherus’ actual results,
performance, or achievements to differ significantly from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Such risks and uncertainties
include, among others, risks related to our existing and potential
collaboration partners, the risks and uncertainties inherent in the
clinical drug development process; risks of the drug development
position of Coherus’ competitors; the risks and uncertainties of
the regulatory approval process, including the speed of regulatory
review, the risk of FDA review issues; and the risks and
uncertainties of possible litigation. All forward-looking
statements contained in this press release speak only as of the
date of this press release. Coherus undertakes no obligation to
update or revise any forward-looking statements. For a further
description of the significant risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Coherus’
business in general, see Coherus’ Quarterly Report on Form 10-Q for
the fiscal quarter ended March 31, 2023, filed with the Securities
and Exchange Commission on May 8, 2023, including the section
therein captioned “Risk Factors” and in other documents that
Coherus files with the Securities and Exchange Commission.
UDENYCA®, CIMERLI® and YUSIMRY™, whether or not appearing in
large print or with the trademark symbol, are trademarks of
Coherus, its affiliates, related companies or its licensors or
joint venture partners unless otherwise noted. Trademarks and trade
names of other companies appearing in this press release are, to
the knowledge of Coherus, the property of their respective
owners.
Coherus BioSciences Contact Information:
IR ContactMarek Ciszewski, J.D.SVP, Investor
RelationsIR@coherus.com
Media ContactJodi SieversVP, Corporate
Communicationsmedia@coherus.com
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Jul 2023 to Jul 2024